Symbols

GENB

Generate Biomedicines·NASDAQ

--(--)

GENB Profile

Generate Biomedicines, Inc.

A clinical stage generative biology company

Industry

Biological Technology

Established Date

Listing Date

02/27/2026

Exchange

NASDAQ Stock Exchange

Full-time Employees

312

Fiscal Year Ends

12-31

Website

www.generatebiomedicines.com

Security Type

Common stock

Office address

101 South Street Suite 900 Somerville MA 02143

Business

Introduction

Generate Biomedicines, Inc., was incorporated under the laws of the State of Delaware in August 2018. As a clinical stage generative biology company, the company pioneered an artificial intelligence-driven biotechnology platform called Generate Platform, which combines computational models with scalable biological hardware to design and develop novel therapeutic proteins. Its most advanced drug candidate, GB-0895, is a computationally engineered anti-TSLP monoclonal antibody that is currently in a pivotal Phase 3 trial for severe asthma. The platform's capabilities have been further demonstrated by advancing two additional oncology drug candidates to Phase 1 trials in 2026.